Globus Medical (GMED)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.34B
Last updated: Nov 17, 2026 at 5:25 PM ET
Globus Medical (GMED) Statistics
Globus Medical (GMED) has a market cap of $9.34B and an enterprise value of $8.90B. Its trailing P/E of 14.1x is below its 10-year median of 27.7x.
Total Valuation
Enterprise value is 4.72% below the market cap, as cash exceeds debt.
| Market Cap | $9.34B |
|---|---|
| Enterprise Value | $8.90B |
| Latest price (Nov 17, 2026) | $70.02 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.0x and 2.0x. Its year-end P/E ranged from 20.8x to 45.6x from 2016 to 2025.
| P/E Ratio | 14.1x |
|---|---|
| Forward P/E | 13.8x |
| P/S Ratio | 3.0x |
| Forward P/S | 3.0x |
| P/B Ratio | 2.0x |
| P/TBV Ratio | 3.5x |
| P/FCF Ratio | 12.3x |
| P/OCF Ratio | 10.1x |
| PEG Ratio | 1.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 9.3x EBITDA and 11.7x free cash flow.
| EV / Earnings | 16.0x |
|---|---|
| EV / Sales | 2.8x |
| EV / EBITDA | 9.3x |
| EV / FCF | 11.7x |
Price Statistics
The stock is down 17.09% over 52 weeks and trades 8.23% below its 50-day average.
| Beta (1Y) | 0.91 |
|---|---|
| 52-Week Change | -17.09% |
| 1-Month Change | -7.44% |
| 3-Month Change | -20.74% |
| 6-Month Change | -12.40% |
| 5-Year Change | +1.14% |
| 10-Year Change | +252.69% |
| Total Return (1Y) | -17.09% |
| Total Return (3Y CAGR) | +15.39% |
| Total Return (5Y CAGR) | +0.26% |
| Return vs SPY (1Y) | -27.62% |
| Max Drawdown (1Y) | -27.68% |
| Max Drawdown (3Y) | -44.40% |
| Sharpe Ratio (1Y) | -0.45 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $76.30 |
| 200-Day Average | $82.50 |
| 52-Week Range | $70.14 to $101.40 |
| RSI (14 Days) | 39.0 |
| Average Volume (20 Days) | 1.99M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.30x |
|---|---|
| Quick Ratio | 2.67x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 11.63% over the last 12 months, against a 5-year average of 7.23%.
| Return on Equity (ROE) | 11.63% |
|---|---|
| Return on Assets (ROA) | 10.09% |
| ROE (5Y Average) | 7.23% |
| ROA (5Y Average) | 6.26% |
| ROIC (5Y Average) | 7.03% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 1.19x |
| Receivables Turnover | 4.59x |
| Cash Conversion Cycle | 347 days |
Taxes
Income tax took 20.27% of pretax income over the last 12 months.
| Income Tax (TTM) | $141.76M |
|---|---|
| Effective Tax Rate | 20.27% |
Scores
GMED has an Altman Z-Score of 9.42, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 9.42 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $3.14B over the last 12 months is up 13.35% from the 12 months before.
| Revenue | $3.14B |
|---|---|
| Revenue Growth (YoY) | +13.35% |
| Gross Profit | $2.17B |
| Operating Income | $679.71M |
| Pretax Income | $699.39M |
| Net Income | $557.64M |
| EBITDA | $960.86M |
| Reported EPS (TTM) | $4.97 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 86.80% of the $5.53B in total assets.
| Cash and Equivalents | $441.27M |
|---|---|
| Total Debt | $0 |
| Net Cash | $441.27M |
| Net Cash Per Share | $3.29 |
| Working Capital | $1.67B |
| Shareholder Equity | $4.80B |
| Book Value Per Share | $35.75 |
| Tangible Book Value | $2.68B |
| Tangible Book Per Share | $19.94 |
| Total Assets | $5.53B |
| Total Liabilities | $731.94M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $159.37M of capital spending, operating cash flow left $766.55M of free cash flow.
| Operating Cash Flow | $925.92M |
|---|---|
| Capital Expenditures | $159.37M |
| Free Cash Flow | $766.55M |
| FCF Per Share | $6.85 |
| Depreciation and Amortization | $285.70M |
| Share Repurchases | $324.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 21.65%, against a 5-year average of 14.33%.
| Gross Margin | 69.12% |
|---|---|
| Operating Margin | 21.65% |
| Pretax Margin | 22.28% |
| Net Margin | 17.76% |
| EBITDA Margin | 30.60% |
| FCF Margin | 24.42% |
| Gross Margin (5Y Average) | 68.12% |
| Operating Margin (5Y Average) | 14.33% |
| Net Margin (5Y Average) | 12.88% |
Growth
Revenue grew 42.17% a year over 3 years, and EPS 24.56% a year.
| Revenue Growth (3Y CAGR) | +42.17% |
|---|---|
| Revenue Growth (5Y CAGR) | +30.08% |
| EPS Growth (3Y CAGR) | +24.56% |
| EPS Growth (5Y CAGR) | +22.84% |
| FCF Growth (3Y CAGR) | +77.99% |
| FCF Growth (5Y CAGR) | +34.23% |
| Operating Income Growth (3Y CAGR) | +28.16% |
| Book Value Per Share Growth (2Y CAGR) | +7.65% |
| Tangible Book Per Share Growth (2Y CAGR) | +21.63% |
Dividends and Yields
GMED does not pay a dividend. Its free cash flow yield is 8.16%.
| Earnings Yield | 7.09% |
|---|---|
| FCF Yield | 8.16% |
| Buyback Yield | 3.45% |
| Shareholder Yield | 3.45% |
Peer Position
Against 9 similar companies, GMED has the 9th highest P/E.
P/E RatioPeer median 23.8x
P/S RatioPeer median 3.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.55%
| P/E Ratio | 14.1x vs 23.8x median |
|---|---|
| P/S Ratio | 3.0x vs 3.5x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.35% vs +5.55% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.65% and EPS growth at 15.51% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.65% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +15.51% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GMED
What is GMED's market cap?
Globus Medical has a market cap of $9.34B. Its enterprise value, which adds debt and subtracts cash, is $8.90B.
What is GMED's P/E ratio?
Globus Medical has a trailing P/E ratio of 14.1x and a forward P/E of 13.8x.
How many shares of GMED are outstanding?
Globus Medical has 134.15M shares outstanding. The count is down 0.26% from a year earlier.
Does GMED pay a dividend?
No. Globus Medical does not pay a dividend.
How much debt does GMED have?
Globus Medical has $0 of total debt and $441.27M of cash and equivalents, a net cash position of $441.27M.
GMED pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts